| Methods |
STUDY DESIGN: cross over, single centre Hong Kong. 2weeks.
RANDOMISATION: Yes, no method stated.
BLINDING: double blind, double dummy, matching devices.
WITHDRAWALS/DROP OUTS: 5 described after randomization.
COMPLIANCE: Not assessed
CONFOUNDERS: Not analysed by ITT
QUALITY: Jadad 4. Cochrane B |
| Participants |
N = 55 ENROLLED, 25 RANDOMISED, 20 COMPLETED. Adults, M = 14 F = 6 Mean age: 41.7 (SD 3.2)
BASELINE SEVERITY: Moderate to severe asthma.
INCLUSION : Baseline FEV1 > 30% predicted, > 15% FEV1 reversibility to SABA. Requiring ICS > 800MCG/DAY
EXCLUSION: none stated |
| Interventions |
LONG ACTING BETA AGONIST: Salmeterol 50 mcg BD
SHORT ACTING BETA AGONIST: Albuterol 400 mcg QDS
PLACEBO: placebo BD
DEVICE: Dry powder device‐ diskhaler
TREATMENT PERIOD: 2 weeks
RESCUE: Albuterol 400 mcg PRN
CO‐INTERVENTIONS: ICS all 800‐2000 mcg/day , OS. |
| Outcomes |
OUTCOMES: FEV1, PEF, Rescue use, asthma symptom score, efficacy rating, adverse events. |
| Notes |
No details on Symptom Score‐ or scale. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
Information not available (Cochrane Grade B) |
